阴道与肌内注射孕激素预防高危孕妇早产比较(VICTORIA研究):多中心开放标签随机试验及荟萃分析
韩国多中心开放标签等效性随机试验纳入266名有自发性早产史或宫颈长度<25 mm的孕妇,16-22周随机接受阴道微粒化黄体酮200 mg/日或肌内注射17α-羟孕酮己酸酯250 mg/周,247名纳入意向性分析。37周前早产风险两组无显著差异(22.7% vs 25.8%,P=0.571),差异3.1%(95%CI -7.6至13.8%),在15%等效界值内。荟萃分析显示两种孕激素治疗早产风险无显著差异。
要点
- 阴道黄体酮与肌注17α-羟孕酮己酸酯预防37周前早产风险无显著差异(22.7% vs 25.8%,P=0.571)。
- 两组早产风险差异3.1%(95%CI -7.6至13.8%),在预设15%等效界值内。
- 荟萃分析显示阴道与肌注孕激素治疗的早产风险无显著差异。
核心结论
- 与阴道黄体酮相比,肌注孕激素可能使有自发性早产史或宫颈长度短的女性37周前早产风险增加最多13.8%,或降低最多7.6%。
研究设计与样本
- 多中心、随机、开放标签、等效性试验及荟萃分析,在韩国三级转诊医院进行。
- 266名有自发性早产史或宫颈长度<25 mm的孕妇在16-22周随机分组,247名(阴道组119名、肌注组128名)纳入意向性分析。
- 阴道组每日200 mg微粒化黄体酮,肌注组每周250 mg 17α-羟孕酮己酸酯,按中心和指征分层随机。
- 试验注册于ClinicalTrials.gov(NCT02304237)。
主要发现
- 37周前早产风险两组无显著差异(阴道组22.7% vs 肌注组25.8%,P=0.571)。
- 两组早产风险差异为3.1%(95%CI -7.6至13.8%),在15%等效界值内。
- 荟萃分析结果显示阴道与肌注孕激素治疗的早产风险无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and to review the relevant literature. DESIGN: A multicentre, randomised, open-label, equivalence trial and a meta-analysis. SETTING: Tertiary referral hospitals in South Korea. POPULATION: Pregnant women with a history of spontaneous PTB or short cervical length (<25 mm). METHODS: Eligible women were screened and randomised at 16-22 weeks of gestation to receive either 200 mg of vaginal micronised progesterone daily (vaginal group) or an intramuscular injection of 250 mg 17α-hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications for progestogen therapy. This trial was registered at ClinicalTrials.gov (NCT02304237). MAIN OUTCOME MEASURE: Preterm birth (PTB) before 37 weeks of gestation. RESULTS: A total of 266 women were randomly assigned and a total of 247 women (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention-to-treat analysis. Risks of PTB before 37 weeks of gestation did not significantly differ between the two groups (22.7 versus 25.8%, P = 0.571). The difference in PTB risk between the two groups was 3.1% (95% CI -7.6 to 13.8%), which was within the equivalence margin of 15%. The meta-analysis results showed no significant differences in the risk of PTB between the vaginal and IM progestogen treatments. CONCLUSION: Compared with vaginal progesterone, treatment with intramuscular progestin might increase the risk of PTB before 37 weeks of gestation by as much as 13.8%, or reduce the risk by as much as 7.6%, in women with a history of spontaneous PTB or with short cervical length. TWEETABLE ABSTRACT: Vaginal and intramuscular progestogen showed equivalent efficacy for preventing preterm birth before 37 weeks of gestation.
引用
- Choi SJ, Kwak DW, Kil K, et al. Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis. BJOG. 2020. PMID: 32536019. doi:10.1111/1471-0528.16365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。